The lipid droplet as a potential therapeutic target in NAFLD

Seminars in Liver Disease

Volumn 33, Issue 4, 2013, Pages 312-320

  Goh, Vera J ^a   Silver, David L ^a  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

lipid droplets; nonalcoholic fatty liver disease; triglyceride

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CHOLESTEROL ACYLTRANSFERASE; CHOLINE PHOSPHATE CYTIDYLYLTRANSFERASE; DIACYLGLYCEROL ACYLTRANSFERASE 1; FAT DROPLET; FAT INDUCING TRANSMEMBRANE PROTEIN 1; FAT INDUCING TRANSMEMBRANE PROTEIN 2; LONG CHAIN FATTY ACID COENZYME A LIGASE; MEMBRANE PROTEIN; PERILIPIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOGENESIS; ARTICLE; CELL DIFFERENTIATION; CONGENITAL GENERALIZED LIPODYSTROPHY; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM; HUMAN; HYPERTENSION; LIPID COMPOSITION; LIPID METABOLISM; LIPODYSTROPHY; LIPOGENESIS; LIPOPROTEIN METABOLISM; LIPOPROTEIN SECRETION; LIPOPROTEIN SYNTHESIS; LIVER CELL; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROTEIN ASSEMBLY; RISK FACTOR; TRANSACTIVATION; WEIGHT REDUCTION;

ANIMALS; FATTY LIVER; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS; LIVER; ORGANELLES; TRIGLYCERIDES;

EID: 84887567812     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0033-1358521     Document Type: Article

References (120)

1. Lazo M., Hernaez R., Eberhardt M. S., et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol: 2013; 178 1 38 45
2. Vernon G., Baranova A., Younossi Z. M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther: 2011; 34 3 274 285
3. Souza M. R., Diniz MdeF, Medeiros-Filho J. E., Araújo M. S. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol: 2012; 49 1 89 96
4. Musso G., Cassader M., Rosina F., Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia: 2012; 55 4 885 904
5. Mark N., de Alwis W., Day C. P. Current and future therapeutic strategies in NAFLD. Curr Pharm Des: 2010; 16 17 1958 1962
6. Nakajima K. Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease. Int J Hepatol: 2012; 2012 950693
7. Eguchi A., Povero D., Alkhouri N., Feldstein A. E. Novel therapeutic targets for nonalcoholic fatty liver disease. Expert Opin Ther Targets: 2013; 17 7 773 779
8. Lomonaco R., Sunny N. E., Bril F., Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs: 2013; 73 1 1 14
9. Xiao J., Guo R., Fung M. L., Liong E. C., Tipoe G. L. Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges. Hepatobiliary Pancreat Dis Int: 2013; 12 2 125 135
10. Welsh J. A., Karpen S., Vos M. B. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr: 2013; 162 3 496 500, e1
11. Perlemuter G., Bigorgne A., Cassard-Doulcier A. M., Naveau S. Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nat Clin Pract Endocrinol Metab: 2007; 3 6 458 469
12. Byrne C. D., Olufadi R., Bruce K. D., Cagampang F. R., Ahmed M. H. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond): 2009; 116 7 539 564
13. Smith B. W., Adams L. A. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci: 2011; 48 3 97 113
14. Karlas T., Wiegand J., Berg T. Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best Pract Res Clin Endocrinol Metab: 2013; 27 2 195 208
15. Tuyama A. C., Chang C. Y. Non-alcoholic fatty liver disease. J Diabetes: 2012; 4 3 266 280
16. Moore J. B. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc: 2010; 69 2 211 220
17. Musso G., Gambino R., Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev: 2010; 11 6 430 445
18. Bartz R., Li W. H., Venables B., et al. Lipidomics reveals that adiposomes store ether lipids and mediate phospholipid traffic. J Lipid Res: 2007; 48 4 837 847
19. Tauchi-Sato K., Ozeki S., Houjou T., Taguchi R., Fujimoto T. The surface of lipid droplets is a phospholipid monolayer with a unique fatty acid composition. J Biol Chem: 2002; 277 46 44507 44512
20. Cermelli S., Guo Y., Gross S. P., Welte M. A. The lipid-droplet proteome reveals that droplets are a protein-storage depot. Curr Biol: 2006; 16 18 1783 1795
21. Krahmer N., Hilger M., Kory N., et al. Protein correlation profiles identify lipid droplet proteins with high confidence. Mol Cell Proteomics: 2013; 12 5 1115 1126
22. Fujimoto T., Parton R. G. Not just fat: the structure and function of the lipid droplet. Cold Spring Harb Perspect Biol: 2011; 3 3
23. Zhang P., Na H., Liu Z., et al. Proteomic study and marker protein identification of Caenorhabditis elegans lipid droplets. Mol Cell Proteomics: 2012; 11 8 317 328
24. Zhang H., Wang Y., Li J., et al. Proteome of skeletal muscle lipid droplet reveals association with mitochondria and apolipoprotein a-I. J Proteome Res: 2011; 10 10 4757 4768
25. Larsson S., Resjö S., Gomez M. F., James P., Holm C. Characterization of the lipid droplet proteome of a clonal insulin-producing β-cell line (INS-1 832/13). J Proteome Res: 2012; 11 2 1264 1273
26. Beller M., Riedel D., Jänsch L., et al. Characterization of the drosophila lipid droplet subproteome. Mol Cell Proteomics: 2006; 5 6 1082 1094
27. Grillitsch K., Connerth M., Köfeler H., et al. Lipid particles/droplets of the yeast Saccharomyces cerevisiae revisited: lipidome meets proteome. Biochim Biophys Acta: 2011; 1811 12 1165 1176
28. Ivashov V. A., Grillitsch K., Koefeler H., et al. Lipidome and proteome of lipid droplets from the methylotrophic yeast Pichia pastoris. Biochim Biophys Acta: 2013; 1831 2 282 290
29. Ohsaki Y., Maeda T., Maeda M., Tauchi-Sato K., Fujimoto T. Recruitment of TIP47 to lipid droplets is controlled by the putative hydrophobic cleft. Biochem Biophys Res Commun: 2006; 347 1 279 287
30. Wolins N. E., Quaynor B. K., Skinner J. R., et al. OXPAT/PAT-1 is a PPAR-induced lipid droplet protein that promotes fatty acid utilization. Diabetes: 2006; 55 12 3418 3428
31. Bickel P. E., Tansey J. T., Welte M. A. PAT proteins, an ancient family of lipid droplet proteins that regulate cellular lipid stores. Biochim Biophys Acta: 2009; 1791 6 419 440
32. Wolins N. E., Quaynor B. K., Skinner J. R., Schoenfish M. J., Tzekov A., Bickel P. E. S3-12, Adipophilin, and TIP47 package lipid in adipocytes. J Biol Chem: 2005; 280 19 19146 19155
33. Straub B. K., Stoeffel P., Heid H., Zimbelmann R., Schirmacher P. Differential pattern of lipid droplet-associated proteins and de novo perilipin expression in hepatocyte steatogenesis. Hepatology: 2008; 47 6 1936 1946
34. Okumura T. Role of lipid droplet proteins in liver steatosis. J Physiol Biochem: 2011; 67 4 629 636
35. Dalen K. T., Schoonjans K., Ulven S. M., et al. Adipose tissue expression of the lipid droplet-associating proteins S3-12 and perilipin is controlled by peroxisome proliferator-activated receptor-gamma. Diabetes: 2004; 53 5 1243 1252
36. Motomura W., Inoue M., Ohtake T., et al. Up-regulation of ADRP in fatty liver in human and liver steatosis in mice fed with high fat diet. Biochem Biophys Res Commun: 2006; 340 4 1111 1118
37. Matsusue K., Kusakabe T., Noguchi T., et al. Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27. Cell Metab: 2008; 7 4 302 311
38. Gavrilova O., Haluzik M., Matsusue K., et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem: 2003; 278 36 34268 34276
39. Inoue M., Ohtake T., Motomura W., et al. Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. Biochem Biophys Res Commun: 2005; 336 1 215 222
40. Panasyuk G., Espeillac C., Chauvin C., et al. PPARγ contributes to PKM2 and HK2 expression in fatty liver. Nat Commun: 2012; 3 672
41. Yamazaki T., Shiraishi S., Kishimoto K., Miura S., Ezaki O. An increase in liver PPARγ2 is an initial event to induce fatty liver in response to a diet high in butter: PPARγ2 knockdown improves fatty liver induced by high-saturated fat. J Nutr Biochem: 2011; 22 6 543 553
42. Schadinger S. E., Bucher N. L., Schreiber B. M., Farmer S. R. PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab: 2005; 288 6 E1195 E1205
43. Zhang Y. L., Hernandez-Ono A., Siri P., et al. Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. J Biol Chem: 2006; 281 49 37603 37615
44. Greco D., Kotronen A., Westerbacka J., et al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol: 2008; 294 5 G1281 G1287
45. Lee B., Zhu J., Wolins N. E., Cheng J. X., Buhman K. K. Differential association of adipophilin and TIP47 proteins with cytoplasmic lipid droplets in mouse enterocytes during dietary fat absorption. Biochim Biophys Acta: 2009; 1791 12 1173 1180
46. Carr R. M., Patel R. T., Rao V., et al. Reduction of TIP47 improves hepatic steatosis and glucose homeostasis in mice. Am J Physiol Regul Integr Comp Physiol: 2012; 302 8 R996 -R1003
47. Fisher E. A., Ginsberg H. N. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem: 2002; 277 20 17377 17380
48. Olofsson S. O., Stillemark-Billton P., Asp L. Intracellular assembly of VLDL: two major steps in separate cell compartments. Trends Cardiovasc Med: 2000; 10 8 338 345
49. Raabe M., Véniant M. M., Sullivan M. A., et al. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J Clin Invest: 1999; 103 9 1287 1298
50. Jamil H., Dickson J. K. Jr, Chu C. H., et al. Microsomal triglyceride transfer protein. Specificity of lipid binding and transport. J Biol Chem: 1995; 270 12 6549 6554
51. Ginsberg H. N., Fisher E. A. The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism. J Lipid Res: 2009; 50 (Suppl): S162 S166
52. Hooper A. J., van Bockxmeer F. M., Burnett J. R. Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism. Crit Rev Clin Lab Sci: 2005; 42 5-6 515 545
53. Linton M. F., Farese R. V. Jr, Young S. G. Familial hypobetalipoproteinemia. J Lipid Res: 1993; 34 4 521 541
54. Tarugi P., Averna M., Di Leo E., et al. Molecular diagnosis of hypobetalipoproteinemia: an ENID review. Atherosclerosis: 2007; 195 2 e19 e27
55. Ye J., Li J. Z., Liu Y., et al. Cideb, an ER- and lipid droplet-associated protein, mediates VLDL lipidation and maturation by interacting with apolipoprotein B. Cell Metab: 2009; 9 2 177 190
56. Gusarova V., Seo J., Sullivan M. L., Watkins S. C., Brodsky J. L., Fisher E. A. Golgi-associated maturation of very low density lipoproteins involves conformational changes in apolipoprotein B, but is not dependent on apolipoprotein E. J Biol Chem: 2007; 282 27 19453 19462
57. Gusarova V., Brodsky J. L., Fisher E. A. Apolipoprotein B100 exit from the endoplasmic reticulum (ER) is COPII-dependent, and its lipidation to very low density lipoprotein occurs post-ER. J Biol Chem: 2003; 278 48 48051 48058
58. Tiwari S., Siddiqi S., Siddiqi S. A. CideB protein is required for the biogenesis of very low density lipoprotein (VLDL) transport vesicle. J Biol Chem: 2013; 288 7 5157 5165
59. Li X., Ye J., Zhou L., Gu W., Fisher E. A., Li P. Opposing roles of cell death-inducing DFF45-like effector B and perilipin 2 in controlling hepatic VLDL lipidation. J Lipid Res: 2012; 53 9 1877 1889
60. Chang B. H., Li L., Paul A., et al. Protection against fatty liver but normal adipogenesis in mice lacking adipose differentiation-related protein. Mol Cell Biol: 2006; 26 3 1063 1076
61. Imai Y., Varela G. M., Jackson M. B., Graham M. J., Crooke R. M., Ahima R. S. Reduction of hepatosteatosis and lipid levels by an adipose differentiation-related protein antisense oligonucleotide. Gastroenterology: 2007; 132 5 1947 1954
62. Magnusson B., Asp L., Boström P., et al. Adipocyte differentiation-related protein promotes fatty acid storage in cytosolic triglycerides and inhibits secretion of very low-density lipoproteins. Arterioscler Thromb Vasc Biol: 2006; 26 7 1566 1571
63. Summers S. A. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res: 2006; 45 1 42 72
64. Chavez J. A., Summers S. A. Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms. Biochim Biophys Acta: 2010; 1801 3 252 265
65. Cusi K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin Liver Dis: 2009; 13 4 545 563
66. Cantley J. L., Yoshimura T., Camporez J. P., et al. CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol- mediated hepatic insulin resistance. Proc Natl Acad Sci U S A: 2013; 110 5 1869 1874
67. Haas J. T., Winter H. S., Lim E., et al. DGAT1 mutation is linked to a congenital diarrheal disorder. J Clin Invest: 2012; 122 12 4680 4684
68. Ables G. P., Yang K. J., Vogel S., et al. Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying. J Lipid Res: 2012; 53 11 2364 2379
69. Buhman K. K., Smith S. J., Stone S. J., et al. DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis. J Biol Chem: 2002; 277 28 25474 25479
70. Bozza P. T., Yu W., Penrose J. F., Morgan E. S., Dvorak A. M., Weller P. F. Eosinophil lipid bodies: specific, inducible intracellular sites for enhanced eicosanoid formation. J Exp Med: 1997; 186 6 909 920
71. D'Avila H., Melo R. C., Parreira G. G., Werneck-Barroso E., Castro-Faria-Neto H. C., Bozza P. T. Mycobacterium bovis bacillus Calmette-Guérin induces TLR2-mediated formation of lipid bodies: intracellular domains for eicosanoid synthesis in vivo. J Immunol: 2006; 176 5 3087 3097
72. 2 generation and increased parasite growth. J Infect Dis: 2011; 204 6 951 961
73. Vieira-de-Abreu A., Assis E. F., Gomes G. S., et al. Allergic challenge-elicited lipid bodies compartmentalize in vivo leukotriene C4 synthesis within eosinophils. Am J Respir Cell Mol Biol: 2005; 33 3 254 261
74. Wang C. W., Lee S. C. The ubiquitin-like (UBX)-domain-containing protein Ubx2/Ubxd8 regulates lipid droplet homeostasis. J Cell Sci: 2012; 125 Pt 12 2930 2939
75. Mantzaris M. D., Tsianos E. V., Galaris D. Interruption of triacylglycerol synthesis in the endoplasmic reticulum is the initiating event for saturated fatty acid-induced lipotoxicity in liver cells. FEBS J: 2011; 278 3 519 530
76. Jo Y., Hartman I. Z., DeBose-Boyd R. A. Ancient ubiquitous protein-1 mediates sterol-induced ubiquitination of 3-hydroxy-3-methylglutaryl CoA reductase in lipid droplet-associated endoplasmic reticulum membranes. Mol Biol Cell: 2013; 24 3 169 183
77. Suzuki M., Otsuka T., Ohsaki Y., et al. Derlin-1 and UBXD8 are engaged in dislocation and degradation of lipidated ApoB-100 at lipid droplets. Mol Biol Cell: 2012; 23 5 800 810
78. Forte T. M., Shu X., Ryan R. O. The ins (cell) and outs (plasma) of apolipoprotein A-V. J Lipid Res: 2009; 50 (Suppl): S150 S155
79. Ploegh H. L. A lipid-based model for the creation of an escape hatch from the endoplasmic reticulum. Nature: 2007; 448 7152 435 438
80. Zhou M., Fisher E. A., Ginsberg H. N. Regulated co-translational ubiquitination of apolipoprotein B100. A new paradigm for proteasomal degradation of a secretory protein. J Biol Chem: 1998; 273 38 24649 24653
81. Olzmann J. A., Kopito R. R. Lipid droplet formation is dispensable for endoplasmic reticulum-associated degradation. J Biol Chem: 2011; 286 32 27872 27874
82. Herker E., Ott M. Emerging role of lipid droplets in host/pathogen interactions. J Biol Chem: 2012; 287 4 2280 2287
83. Harris C., Herker E., Farese R. V. Jr, Ott M. Hepatitis C virus core protein decreases lipid droplet turnover: a mechanism for core-induced steatosis. J Biol Chem: 2011; 286 49 42615 42625
84. Wilfling F., Wang H., Haas J. T., et al. Triacylglycerol synthesis enzymes mediate lipid droplet growth by relocalizing from the ER to lipid droplets. Dev Cell: 2013; 24 4 384 399
85. Farese R. V. Jr, Walther T. C. Lipid droplets finally get a little R-E-S-P-E-C-T. Cell: 2009; 139 5 855 860
86. Gross D. A., Snapp E. L., Silver D. L. Structural insights into triglyceride storage mediated by fat storage-inducing transmembrane (FIT) protein 2. PLoS ONE: 2010; 5 5 e10796
87. Kadereit B., Kumar P., Wang W. J., et al. Evolutionarily conserved gene family important for fat storage. Proc Natl Acad Sci U S A: 2008; 105 1 94 99
88. Miranda D. A., Koves T. R., Gross D. A., et al. Re-patterning of skeletal muscle energy metabolism by fat storage-inducing transmembrane protein 2. J Biol Chem: 2011; 286 49 42188 42199
89. Gross D. A., Zhan C., Silver D. L. Direct binding of triglyceride to fat storage-inducing transmembrane proteins 1 and 2 is important for lipid droplet formation. Proc Natl Acad Sci U S A: 2011; 108 49 19581 19586
90. Villanueva C. J., Vergnes L., Wang J., et al. Adipose subtype-selective recruitment of TLE3 or Prdm16 by PPARγ specifies lipid storage versus thermogenic gene programs. Cell Metab: 2013; 17 3 423 435
91. Lefterova M. I., Zhang Y., Steger D. J., et al. PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes Dev: 2008; 22 21 2941 2952
92. Moir R. D., Gross D. A., Silver D. L., Willis I. M. SCS3 and YFT2 link transcription of phospholipid biosynthetic genes to ER stress and the UPR. PLoS Genet: 2012; 8 8 e1002890
93. Guo Y., Walther T. C., Rao M., et al. Functional genomic screen reveals genes involved in lipid-droplet formation and utilization. Nature: 2008; 453 7195 657 661
94. Krahmer N., Guo Y., Wilfling F., et al. Phosphatidylcholine synthesis for lipid droplet expansion is mediated by localized activation of CTP:phosphocholine cytidylyltransferase. Cell Metab: 2011; 14 4 504 515
95. Penno A., Hackenbroich G., Thiele C. Phospholipids and lipid droplets. Biochim Biophys Acta: 2013; 1831 3 589 594
96. Hörl G., Wagner A., Cole L. K., et al. Sequential synthesis and methylation of phosphatidylethanolamine promote lipid droplet biosynthesis and stability in tissue culture and in vivo. J Biol Chem: 2011; 286 19 17338 17350
97. Moessinger C., Kuerschner L., Spandl J., Shevchenko A., Thiele C. Human lysophosphatidylcholine acyltransferases 1 and 2 are located in lipid droplets where they catalyze the formation of phosphatidylcholine. J Biol Chem: 2011; 286 24 21330 21339
98. DeLong C. J., Shen Y. J., Thomas M. J., Cui Z. Molecular distinction of phosphatidylcholine synthesis between the CDP-choline pathway and phosphatidylethanolamine methylation pathway. J Biol Chem: 1999; 274 42 29683 29688
99. Shi X., Li J., Zou X., et al. Regulation of lipid droplet size and phospholipid composition by stearoyl-CoA desaturase. J Lipid Res: 2013; 54 9 2504 2514
100. Kim Y. J., Cho S. Y., Yun C. H., Moon Y. S., Lee T. R., Kim S. H. Transcriptional activation of Cidec by PPARgamma2 in adipocyte. Biochem Biophys Res Commun: 2008; 377 1 297 302
101. Viswakarma N., Yu S., Naik S., et al. Transcriptional regulation of Cidea, mitochondrial cell death-inducing DNA fragmentation factor alpha-like effector A, in mouse liver by peroxisome proliferator-activated receptor alpha and gamma. J Biol Chem: 2007; 282 25 18613 18624
102. Puri V., Czech M. P. Lipid droplets: FSP27 knockout enhances their sizzle. J Clin Invest: 2008; 118 8 2693 2696
103. Nishino N., Tamori Y., Tateya S., et al. FSP27 contributes to efficient energy storage in murine white adipocytes by promoting the formation of unilocular lipid droplets. J Clin Invest: 2008; 118 8 2808 2821
104. Jinno Y., Nakakuki M., Sato A., et al. Cide-a and Cide-c are induced in the progression of hepatic steatosis and inhibited by eicosapentaenoic acid. Prostaglandins Leukot Essent Fatty Acids: 2010; 83 2 75 81
105. Zhou L., Xu L., Ye J., et al. Cidea promotes hepatic steatosis by sensing dietary fatty acids. Hepatology: 2012; 56 1 95 107
106. Rubio-Cabezas O., Puri V., Murano I., et al. LD Screening Consortium Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Mol Med: 2009; 1 5 280 287
107. Jambunathan S., Yin J., Khan W., Tamori Y., Puri V. FSP27 promotes lipid droplet clustering and then fusion to regulate triglyceride accumulation. PLoS ONE: 2011; 6 12 e28614
108. Gong J., Sun Z., Wu L., et al. Fsp27 promotes lipid droplet growth by lipid exchange and transfer at lipid droplet contact sites. J Cell Biol: 2011; 195 6 953 963
109. Sun Z., Gong J., Wu H., et al. Perilipin1 promotes unilocular lipid droplet formation through the activation of Fsp27 in adipocytes. Nat Commun: 2013; 4 1594
110. Magré J., Delépine M., Khallouf E., et al. BSCL Working Group Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet: 2001; 28 4 365 370
111. Chen W., Chang B., Saha P., et al. Berardinelli-seip congenital lipodystrophy 2/seipin is a cell-autonomous regulator of lipolysis essential for adipocyte differentiation. Mol Cell Biol: 2012; 32 6 1099 1111
112. Cui X., Wang Y., Tang Y., et al. Seipin ablation in mice results in severe generalized lipodystrophy. Hum Mol Genet: 2011; 20 15 3022 3030
113. Fei W., Li H., Shui G., et al. Molecular characterization of seipin and its mutants: implications for seipin in triacylglycerol synthesis. J Lipid Res: 2011; 52 12 2136 2147
114. Payne V. A., Grimsey N., Tuthill A., et al. The human lipodystrophy gene BSCL2/seipin may be essential for normal adipocyte differentiation. Diabetes: 2008; 57 8 2055 2060
115. Chen W., Yechoor V. K., Chang B. H., Li M. V., March K. L., Chan L. The human lipodystrophy gene product Berardinelli-Seip congenital lipodystrophy 2/seipin plays a key role in adipocyte differentiation. Endocrinology: 2009; 150 10 4552 4561
116. Yang W., Thein S., Guo X., et al. Seipin differentially regulates lipogenesis and adipogenesis through a conserved core sequence and an evolutionarily acquired C-terminus. Biochem J: 2013; 452 1 37 44
117. Cui X., Wang Y., Meng L., et al. Overexpression of a short human seipin/BSCL2 isoform in mouse adipose tissue results in mild lipodystrophy. Am J Physiol Endocrinol Metab: 2012; 302 6 E705 E713
118. Fei W., Shui G., Zhang Y., et al. A role for phosphatidic acid in the formation of supersized lipid droplets. PLoS Genet: 2011; 7 7 e1002201
119. Fei W., Du X., Yang H. Seipin, adipogenesis and lipid droplets. Trends Endocrinol Metab: 2011; 22 6 204 210
120. Tian Y., Bi J., Shui G., et al. Tissue-autonomous function of Drosophila seipin in preventing ectopic lipid droplet formation. PLoS Genet: 2011; 7 4 e1001364